LT4780B - Živ proteazės inhibitoriaus rūgštusis sulfatas - Google Patents
Živ proteazės inhibitoriaus rūgštusis sulfatas Download PDFInfo
- Publication number
- LT4780B LT4780B LT2000067A LT2000067A LT4780B LT 4780 B LT4780 B LT 4780B LT 2000067 A LT2000067 A LT 2000067A LT 2000067 A LT2000067 A LT 2000067A LT 4780 B LT4780 B LT 4780B
- Authority
- LT
- Lithuania
- Prior art keywords
- free base
- solubility
- acid
- sulfate
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7196898P | 1998-01-20 | 1998-01-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
LT2000067A LT2000067A (en) | 2000-11-27 |
LT4780B true LT4780B (lt) | 2001-04-25 |
Family
ID=22104737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LT2000067A LT4780B (lt) | 1998-01-20 | 2000-07-14 | Živ proteazės inhibitoriaus rūgštusis sulfatas |
Country Status (39)
Country | Link |
---|---|
US (1) | US6087383A (es) |
EP (1) | EP1056722B1 (es) |
JP (2) | JP4860037B2 (es) |
KR (1) | KR100559283B1 (es) |
CN (1) | CN1116282C (es) |
AR (1) | AR014417A1 (es) |
AT (1) | ATE219057T1 (es) |
AU (1) | AU735875B2 (es) |
BG (1) | BG64774B1 (es) |
BR (1) | BR9814736A (es) |
CA (1) | CA2317736C (es) |
CO (1) | CO4970820A1 (es) |
CZ (1) | CZ293507B6 (es) |
DE (1) | DE69806067T2 (es) |
DK (1) | DK1056722T3 (es) |
EE (1) | EE04434B1 (es) |
EG (1) | EG23936A (es) |
ES (1) | ES2178300T3 (es) |
GE (1) | GEP20033026B (es) |
HK (2) | HK1033667A1 (es) |
HU (1) | HU227196B1 (es) |
IL (2) | IL137384A0 (es) |
LT (1) | LT4780B (es) |
LV (1) | LV12522B (es) |
MY (1) | MY114838A (es) |
NO (1) | NO315605B1 (es) |
NZ (1) | NZ504417A (es) |
PE (1) | PE20000185A1 (es) |
PL (1) | PL190744B1 (es) |
PT (1) | PT1056722E (es) |
RO (1) | RO118869B1 (es) |
RU (1) | RU2186070C2 (es) |
SK (1) | SK283975B6 (es) |
TR (1) | TR200001876T2 (es) |
TW (1) | TW531531B (es) |
UA (1) | UA59432C2 (es) |
UY (1) | UY25345A1 (es) |
WO (1) | WO1999036404A1 (es) |
ZA (1) | ZA9956B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004534771A (ja) | 2001-05-22 | 2004-11-18 | イーラン ファーマスーティカルズ、インコーポレイテッド | アザヒドロキシル化エチルアミン化合物 |
US7157561B2 (en) * | 2001-07-13 | 2007-01-02 | Roche Diagnostics Operations, Inc. | Methods of inhibiting transmission of a costimulatory signal of lymphocytes |
US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US20040224916A1 (en) * | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
CN1980666B (zh) * | 2004-05-04 | 2011-03-30 | 布里斯托尔-迈尔斯斯奎布公司 | 制备阿扎那韦硫酸氢盐的方法和新的形式 |
US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
TWI354569B (en) * | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7642049B2 (en) | 2006-06-30 | 2010-01-05 | Bristol-Myers Squibb Company | Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms |
CA2657936C (en) * | 2006-07-21 | 2017-01-10 | Gilead Sciences, Inc. | Antiviral protease inhibitors |
BG66056B1 (bg) * | 2006-10-05 | 2010-12-30 | Красимир ДЕЧЕВ | Метод и инсталация за производство на трисезонна добавка към дизелово гориво |
MX2009013565A (es) | 2007-06-12 | 2010-06-02 | Concert Pharmaceuticals Inc | Derivados de azapeptidos. |
US20100183715A1 (en) * | 2007-06-22 | 2010-07-22 | Bristo-Meyers Squibb Company | Tableted compositions containing atazanavir |
DE602008005896D1 (de) * | 2007-06-22 | 2011-05-12 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
AU2008268627A1 (en) * | 2007-06-22 | 2008-12-31 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
AU2008268630A1 (en) * | 2007-06-22 | 2008-12-31 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
KR20100028656A (ko) * | 2007-06-29 | 2010-03-12 | 길리애드 사이언시즈, 인코포레이티드 | 치료 조성물 및 그의 용도 |
TW200914011A (en) * | 2007-06-29 | 2009-04-01 | Gilead Sciences Inc | Therapeutic compositions and methods |
WO2009136365A1 (en) * | 2008-05-08 | 2009-11-12 | Ranbaxy Laboratories Limited | Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof |
WO2010070611A1 (en) | 2008-12-18 | 2010-06-24 | Ranbaxy Laboratories Limited | Atazanavir formulations |
WO2010079497A2 (en) * | 2009-01-12 | 2010-07-15 | Hetero Research Foundation | Novel polymorph of atazanavir sulfate |
CA2762582A1 (en) | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
EP2272830A1 (en) | 2009-06-18 | 2011-01-12 | Esteve Química, S.A. | Preparation process of an antivirally heterocyclic azahexane derivative |
WO2011027324A1 (en) | 2009-09-03 | 2011-03-10 | Ranbaxy Laboratories Limited | Polymorphic forms of atazanavir sulfate |
HRP20211826T1 (hr) | 2009-10-26 | 2022-03-04 | Merck Sharp & Dohme Corp. | Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze |
WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
NZ627826A (en) | 2010-01-27 | 2016-01-29 | Viiv Healthcare Co | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
EP2542527A2 (en) | 2010-03-01 | 2013-01-09 | Lupin Limited | Process for the preparation of atazanavir sulfate substantially free of diastereomers |
US20130203759A1 (en) | 2010-04-09 | 2013-08-08 | Faranak Nikfar | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT |
EA201390464A1 (ru) | 2010-09-28 | 2013-08-30 | Рациофарм Гмбх | Способ сухой обработки атазанавира |
US20140343290A1 (en) | 2011-07-27 | 2014-11-20 | Rakesh Kumar Singh | Process for the preparation of atazanavir or its bisulfate salt |
US8461347B2 (en) | 2011-08-05 | 2013-06-11 | Scinopharm Taiwan, Ltd. | Process for preparing form A of atazanavir sulfate |
US9133157B2 (en) | 2011-10-26 | 2015-09-15 | Merck Canada Inc. | HIV protease inhibitors |
US9382207B2 (en) | 2012-08-24 | 2016-07-05 | Laurus Labs Private Limited | Process for the preparation of atazanavir bisulfate |
WO2014036690A1 (zh) * | 2012-09-04 | 2014-03-13 | 上海迪赛诺化学制药有限公司 | 制备阿扎那韦硫酸氢盐a型结晶的方法 |
ZA201401073B (en) | 2013-02-12 | 2015-12-23 | Cipla Ltd | Process for preparing atazanavir sulphate |
CN104250223B (zh) * | 2013-06-28 | 2017-04-12 | 上海威智医药科技有限公司 | 阿扎那韦氢溴酸盐及其制备和应用 |
CN104250224A (zh) * | 2013-06-28 | 2014-12-31 | 上海威智医药科技有限公司 | 阿扎那韦富马酸盐及其制备和应用 |
CN104250225A (zh) * | 2013-06-28 | 2014-12-31 | 上海威智医药科技有限公司 | 阿扎那韦磷酸盐及其制备和应用 |
CN105859611A (zh) * | 2016-04-18 | 2016-08-17 | 上海现代制药海门有限公司 | 一种阿扎那韦硫酸氢盐a型结晶的制备方法 |
CN109251165B (zh) * | 2018-10-02 | 2022-09-23 | 国药集团川抗制药有限公司 | 阿扎那韦达二4-氨基苯磺酸盐及其制备方法 |
CN111349042B (zh) * | 2018-12-20 | 2023-07-14 | 陕西理工大学 | 一种阿扎那韦单晶及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040029A1 (en) | 1996-04-22 | 1997-10-30 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
-
1998
- 1998-12-21 US US09/217,538 patent/US6087383A/en not_active Expired - Lifetime
- 1998-12-22 RU RU2000119792/04A patent/RU2186070C2/ru active
- 1998-12-22 AU AU20101/99A patent/AU735875B2/en not_active Expired
- 1998-12-22 EP EP98964878A patent/EP1056722B1/en not_active Expired - Lifetime
- 1998-12-22 EE EEP200000798A patent/EE04434B1/xx unknown
- 1998-12-22 CA CA002317736A patent/CA2317736C/en not_active Expired - Lifetime
- 1998-12-22 RO ROA200000717A patent/RO118869B1/ro unknown
- 1998-12-22 BR BR9814736-6A patent/BR9814736A/pt not_active Application Discontinuation
- 1998-12-22 HU HU0101389A patent/HU227196B1/hu unknown
- 1998-12-22 NZ NZ504417A patent/NZ504417A/en not_active IP Right Cessation
- 1998-12-22 CZ CZ20002564A patent/CZ293507B6/cs not_active IP Right Cessation
- 1998-12-22 SK SK1062-2000A patent/SK283975B6/sk not_active IP Right Cessation
- 1998-12-22 IL IL13738498A patent/IL137384A0/xx active IP Right Grant
- 1998-12-22 TR TR2000/01876T patent/TR200001876T2/xx unknown
- 1998-12-22 UA UA2000084931A patent/UA59432C2/uk unknown
- 1998-12-22 ES ES98964878T patent/ES2178300T3/es not_active Expired - Lifetime
- 1998-12-22 PT PT98964878T patent/PT1056722E/pt unknown
- 1998-12-22 AT AT98964878T patent/ATE219057T1/de active
- 1998-12-22 KR KR1020007007885A patent/KR100559283B1/ko not_active IP Right Cessation
- 1998-12-22 PL PL342019A patent/PL190744B1/pl unknown
- 1998-12-22 DK DK98964878T patent/DK1056722T3/da active
- 1998-12-22 CN CN98812741A patent/CN1116282C/zh not_active Expired - Lifetime
- 1998-12-22 JP JP2000540121A patent/JP4860037B2/ja not_active Expired - Lifetime
- 1998-12-22 GE GEAP19985466A patent/GEP20033026B/en unknown
- 1998-12-22 WO PCT/US1998/027382 patent/WO1999036404A1/en active IP Right Grant
- 1998-12-22 DE DE69806067T patent/DE69806067T2/de not_active Expired - Lifetime
-
1999
- 1999-01-05 ZA ZA9900056A patent/ZA9956B/xx unknown
- 1999-01-05 MY MYPI99000020A patent/MY114838A/en unknown
- 1999-01-12 UY UY25345A patent/UY25345A1/es not_active Application Discontinuation
- 1999-01-15 TW TW088100623A patent/TW531531B/zh not_active IP Right Cessation
- 1999-01-17 EG EG5699A patent/EG23936A/xx active
- 1999-01-18 AR ARP990100179A patent/AR014417A1/es active IP Right Grant
- 1999-01-19 CO CO99002578A patent/CO4970820A1/es unknown
- 1999-01-20 PE PE1999000047A patent/PE20000185A1/es not_active IP Right Cessation
-
2000
- 2000-06-06 LV LVP-00-78A patent/LV12522B/en unknown
- 2000-07-14 LT LT2000067A patent/LT4780B/lt not_active IP Right Cessation
- 2000-07-17 BG BG104618A patent/BG64774B1/bg unknown
- 2000-07-19 IL IL137384A patent/IL137384A/en not_active IP Right Cessation
- 2000-07-19 NO NO20003692A patent/NO315605B1/no not_active IP Right Cessation
-
2001
- 2001-04-26 HK HK01103011A patent/HK1033667A1/xx not_active IP Right Cessation
- 2001-06-15 HK HK01104126A patent/HK1033458A1/xx not_active IP Right Cessation
-
2008
- 2008-12-17 JP JP2008321240A patent/JP2009102357A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040029A1 (en) | 1996-04-22 | 1997-10-30 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT4780B (lt) | Živ proteazės inhibitoriaus rūgštusis sulfatas | |
ES2243553T3 (es) | Procedimiento para preparar maleato de amlodipina. | |
CA2514733A1 (en) | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen | |
CS265250B2 (en) | Process for preparing anhydrous crystalline natrium salt of 5-chlor-3-/2-thenoyl/-2-oxindol-1-carboxamide | |
US6828339B2 (en) | Amlodipine salt forms and processes for preparing them | |
WO2023087101A1 (en) | Salts of ruxolitinib and crystalline forms thereof | |
US6737428B2 (en) | BIS hydrochloride monohydrate salt of RSV fusion inhibitor | |
CA3041134A1 (en) | Novel salts of nilotinib and crystalline forms thereof | |
MXPA00006747A (es) | Sal de bisulfato del inhibidor de proteasa de vih | |
SI21703A (en) | Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia | |
US7563794B2 (en) | Ziprasidone free from colored impurities and a process for its preparation | |
NL1018758C1 (nl) | Aspartaatderivaat van amlodipine. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC9A | Transfer of patents |
Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH Effective date: 20130926 |
|
TC9A | Change of representative |
Representative=s name: ZABOLIENE, REDA, LT Effective date: 20130926 |
|
MK9A | Expiry of a patent |
Effective date: 20181222 |